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Abstract
Study Objectives: This study examined how glucose, glucose regulatory hormones, insulin sensitivity, and lipoprotein 
subclass particle concentrations and sizes change with sleep restriction during weight loss elicited by calorie restriction.
Methods: Overweight or obese adults were randomized into an 8-week calorie restriction intervention alone (CR, n = 12; 
75% female; body mass index = 31.4 ± 2.9 kg/m2) or combined with sleep restriction (CR+SR, n = 16; 75% female; body mass 
index = 34.5 ± 3.1 kg/m2). Participants in both groups were given the same instructions to reduce calorie intake. Those in 
the CR+SR group were instructed to reduce their habitual time-in-bed by 30–90 minutes 5 days each week with 2 ad libitum 
sleep days. Fasting venous blood samples were collected at pre- and post-intervention.
Results: Differential changes were found between the two groups (p = 0.028 for group × time interaction) in glucagon 
concentration, which decreased in the CR group (p = 0.016) but did not change in CR+SR group. Although changes in mean 
Statement of Significance
This study adds important information to the literature regarding the effects of sleep restriction in the context of calorie 
restriction on health outcomes. The 8-week intervention used in this study is longer than many other controlled studies 
examining sleep restriction. Another feature of the study is that sleep restriction was on 5 days a week (≤90 minutes per 
day), and ad libitum sleep was on the other 2 days. Thus, the study design allows the results to have greater generaliz-
ability to populations in real life. Differential changes were found in serum glucagon concentrations between the groups 
undergoing calorie restriction with and without sleep restriction. Results also suggest differential changes in mean HDL 
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HDL particle (HDL-P) size and visfatin concentration were not statistically different between groups (p = 0.066 and 0.066 
for group×time interaction, respectively), mean HDL-P size decreased only in the CR+SR group (Cohen’s d = 0.50, p = 0.022); 
visfatin concentrations did not change significantly in either group but appeared to decrease in the CR group (Cohen’s 
d = 0.67, p = 0.170) but not in the CR+SR group (Cohen’s d = 0.43, p = 0.225).
Conclusion: These results suggest that moderate sleep restriction, despite the presence of periodic ad libitum sleep, 
influences lipoprotein subclass particles and glucose regulation in individuals undergoing calorie restriction.
Clinical trial registration: ClinicalTrials.gov (NCT02413866, Weight Outlooks by Restriction of Diet and Sleep)
Key words:  sleep restriction; catch-up sleep; weight loss; lipoprotein particles; glucagon; visfatin
Introduction
An estimated 71.6% of adults in the United States are classified 
as overweight or obese [1]. Excess adiposity is known to increase 
the risk for the development of impaired glucose metabolism, 
insulin sensitivity, and lipoprotein cholesterol profile [2, 3], and 
to increase the risk for diabetes and cardiovascular diseases [4, 
5]. Weight loss, even a modest amount, improves glucose me-
tabolism and insulin sensitivity [6]. Weight loss also improves 
traditional lipoprotein cholesterol profile, which includes 
total cholesterol, low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), and triglyceride 
(TG) concentrations [7, 8]. However, lipoprotein particles are 
heterogeneous consisting of particles of a variety of sizes, with 
smaller particles carrying less cholesterol. LDL particle (LDL-P) 
concentration was a better indicator of atherosclerotic risk and 
peripheral artery disease than LDL-C in large-scale studies [9–
11]. Low concentrations of HDL particles (HDL-P) were revealed 
to be superior to low HDL-C in terms of cardiovascular risk pre-
diction [12]. Low mean HDL-P size was also associated with 
cardiovascular disease which may be secondary to the associ-
ations of HDL-P and HDL-C numbers to cardiovascular disease 
[12]. Reductions in small very-low-density lipoprotein particle 
(VLDL-P) concentration was found to be associated with reduc-
tions in atherosclerotic cardiovascular disease, independent of 
LDL-C [13]. As such, lipoprotein subclass particle concentrations 
and sizes are potentially better predictors of cardiovascular dis-
ease risks than traditional lipoprotein cholesterol profile. Few 
studies have examined the impact of weight loss on lipoprotein 
particle concentrations or sizes, and their results suggest that 
LDL-P size increased following weight loss [14, 15].
Insufficient sleep has also been found to influence glucose 
metabolism and insulin sensitivity [16–18]. Previously, glucose 
tolerance and insulin sensitivity were reduced after several 
nights of 4–5 hours of time-in-bed (TIB) per night compared to 
≥8.5 hours TIB [19, 20]. More recent evidence showed that even 
an average of one-hour sleep restriction on three consecutive 
nights reduced insulin sensitivity compared to after three con-
secutive nights of ad libitum sleep [21]. Further, Depner et  al. 
[22] reported that a weekend of recovery sleep did not prevent 
the reduced insulin sensitivity associated with recurrent insuf-
ficient sleep of two nights. These studies suggest that a short 
period of daily sleep restriction adversely affects glucose metab-
olism and insulin sensitivity. However, Zielinski et al. found no 
changes in glucose tolerance after 8 weeks of 90 minutes TIB re-
striction per night [23]. Thus, over a longer-period, the effects of 
sleep restriction on glucose metabolism and insulin sensitivity 
might be different from that of a short period.
Lipoprotein cholesterol profile has also been found to be as-
sociated with sleep duration. Shorter than 6 hours of sleep per 
night and longer than 8 hours of sleep per night are associated 
with higher total cholesterol, LDL-C, and TG concentrations, and 
associated with lower HDL-C concentration [24, 25]. In popula-
tion cohorts, individuals reporting insufficient sleep had lower 
large HDL particle (HDL-P) concentrations than those reporting 
sufficient sleep [26]. Studies have also shown that a few days of 
sleep restriction influenced lipid metabolism [27, 28], and de-
creased small, medium, and large LDL-P, and small very-low-
density lipoprotein particle (VLDL-P) concentrations [26].
The effects of sleep restriction during weight loss on glucose 
metabolism and insulin sensitivity is less studied, and we are not 
aware of published studies on changes in lipoprotein subclass. 
Nedeltcheva et al. examined the effects of a 14-day hypocaloric 
dietary weight loss program with two different sleep conditions, 
5.5 hours of TIB and 8.5 hours of TIB [29]. Following the short-
ened sleep condition, fasting glucose and 24-hour average in-
sulin concentration were significantly lower compared to the 
longer sleep condition. St-Onge et  al. studied normal-weight 
adults following 4 hours of TIB and 9 hours of TIB over 5 con-
secutive nights while maintaining the same controlled diet [30]. 
Although the controlled diet was not designed to be hypocaloric, 
participants lost a small amount of weight of approximately 
0.9 kg on average following both conditions. No differences in 
glucose or insulin concentrations were found between the sleep 
conditions. The results of these two studies [29, 30] seem to be 
different from those in the other abovementioned studies [17, 
19–22], thus suggesting the effect of sleep restriction on glucose 
metabolism and insulin sensitivity may be influenced by weight 
loss. However, the durations of the sleep restriction intervention 
in these studies were short (14 and 5 days, respectively), and the 
effects of insufficient sleep on glucose metabolism and insulin 
sensitivity in a longer-term sleep restriction intervention and in 
the context of hypocaloric diet has not been studied.
Therefore, the aim of this exploratory study was to examine 
the effects of moderate sleep restriction of less than or equal to 
(≤) 90 minutes of nightly TIB during an 8-week calorie restric-
tion program on glucose concentrations, insulin sensitivity, 
hormones associated with glucose metabolism, and lipopro-
tein subclass particle sizes and concentrations in overweight 
or obese adults. We hypothesized that sleep restriction during 
calorie restriction would negatively impact glucose metabolism 
compared to calorie restriction alone in overweight or obese 
adults.
Methods
Data were obtained from the Weight Outlooks by Restriction 
of Diet and Sleep (WORDS) study (ClinicalTrials.gov identifier: 
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design to examine the influence of sleep restriction on out-
comes associated with 8-week calorie restriction. Primary re-
sults on body composition have been previously described [31]. 
The study protocol was approved by the University of South 
Carolina Institutional Review Board and all participants signed 
an informed consent form prior to participation. Figure 1 shows 
the sample sizes from the parent study to the present study, 
which included 28 participants who had lipoprotein subclass 
data at pre- and post-intervention. Of these participants, 23 also 
had glucose regulatory hormone data available.
Participants and intervention groups
Participants were 35–55 years of age, overweight or obese [25 ≤ 
body mass index (BMI) ≤ 40  kg/m2], weight stable (≤3% body 
weight change) during the previous 3  months and did not 
smoke during the past year. No female participant was preg-
nant or lactating. None of the participants reported having 
been diagnosed with diabetes; however, we did not purposely 
screen for diabetes. Participants who were taking medications 
had been taking those in a stable dose for >6 months prior to 
participating in the study. Specifically, 4 participants reported 
taking lipid or glucose-controlling medications. No participant 
was a shift worker, nor had work that required long-distance 
driving or operating heavy equipment. All participants reported 
current 24-hour sleep duration was 6.5–8 hours, including naps 
of <90 min/day, and no use of medications, devices, or hypnotics 
to help sleep. Further, participants were assessed for sleep 
apnea utilizing a WatchPat monitoring device (Itamar Medical, 
Israel) at home for one night, and no one had signs of severe 
sleep apnea (i.e. apnea-hypopnea index ≥ 30). All participants 
were informed of potential safety issues associated with mod-
erate sleep restriction during an individual orientation prior to 
participation in the study.
Participants were randomized into one of two 8-week 
interventions, calorie restriction alone or combined with 
sleep restriction (CR and CR+SR, respectively), following pre-
intervention measurements. The present study included 12 par-
ticipants in the CR group and 16 in the CR+SR group (Figure 1). 
During the intervention, all participants were asked to maintain 
normal daily activities and to not participate in other interven-
tional research studies.
Calorie restriction
All participants were instructed to self-report all calorie-
containing items consumed, including any beverages or snacks, 
for one week prior to the intervention, throughout the inter-
vention, and 1 week after completion of the intervention. 
Participants were instructed on using the MyFitnessPal appli-
cation (MyFitnessPal, Inc.) that is available on smartphones 
or web-based devices. If a smartphone or computer was un-
available, participants were provided with a self-report paper 
form to record any calorie-containing food or drink consumed, 
including portion size, calories, and macronutrient breakdown 
(carbohydrate, protein, and fat) utilizing The Calorie King Calorie 
Counter.
Each individual’s resting metabolic rate was measured, and 
95% of this value was calculated and used as a daily calorie in-
take goal for each respective participant [31]. Prepackaged meals, 
based on each participant’s calorie intake goals, were provided 
for lunch and dinner 4 days each week during the intervention. 
These meals also served as samples that meet the calorie in-
take goal for participants. Dietary instruction was provided to 
each participant for breakfast and snacks throughout the day, as 
well as during the 3 days of ad libitum food consumption when 
participants were able to eat freely. Each week research staff col-
lected the dietary records and reviewed with participants.
Sleep restriction
Participants wore an actigraphy monitor (ActiGraph GT3X+, 
ActiGraph, Pensacola, FL) on their non-dominant wrist for a week 
prior to the intervention, throughout the 8-week intervention, and 
for a week after the intervention to evaluate sleep. Participants 
were also instructed to maintain a sleep diary during these days re-
cording time getting into bed, lights turned off and trying to sleep, 
waking up, and getting out of bed, and any naps taken throughout 
the day. Sleep diaries and actigraphy recordings were reviewed by 
staff and any issue was discussed with the participant each week.
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For the CR+SR group, participants were directed to reduce 
their total TIB by a minimum of 30 minutes and up to 90 minutes 
on 5 nights per week, and to sleep freely on the other 2 nights 
each week. To aid in retention and adherence to the CR+SR 
group, each participant chose their own sleep restricted and ad 
libitum sleep days, and allowed a range of TIB reduction between 
30 and 90 minutes. Participants were instructed to achieve this 
reduction by going to bed later, getting up earlier, or a combin-
ation of both, and maintaining their nap habits. Participants 
were also asked to maintain their sleep schedule throughout 
the 8-week intervention and to not shift nightly sleep schedules. 
Participants in the CR only group were instructed to maintain 
their daily sleep and nap habits throughout the study.
Output from the monitors was analyzed using the ActiLife 
6.11 software program provided by the manufacturer. Minute-
by-minute asleep/awake status was determined using the 
Cole-Kripke Algorithm [32]. Self-reported times from the sleep 
diary were entered into the ActiLife software program to help 
quantify total sleep time (TST) and TIB for each participant. 
TST was defined as the total number of minutes considered 
asleep by the actigraphy device, while TIB was total time from 
getting into bed with lights off trying to sleep until getting out 
of bed plus any naps recorded by the participant throughout 
the day. The difference in midpoint of nightly TIB during sleep 
restricted days and ad libitum days for participants in the 
CR+SR group was calculated. The difference in midpoint of 
TIB on workdays and free days for those in the CR group was 
also calculated.
To monitor adverse changes due to the interven-
tion, all participants were asked to complete the Center 
for Epidemiological Studies Depression Scale (CES-D) [33], 
Epworth Sleepiness Scale (ESS) [34], Functional Outcomes 
of Sleep Questionnaire (FOSQ) [35], Pittsburg Sleep Quality 
Index (PSQI) [36], the 36-Item Short Form (SF-36) [37], and 
Psychomotor Vigilance Test (PVT) [38, 39] at pre-intervention 
and every 2 weeks during the intervention. Indications for ex-
clusion from the study were set at clinical depression (CES-D 
> 16), excessive sleepiness (ESS > 12), a change >10% in FOSQ, 
or PVT response time >500  ms. No participant experienced 
changes based on these criteria that would be considered ex-
clusionary from the study.
Measurements
Height, body weight, and physical activity
Height was measured using a stadiometer at pre- and post-
intervention. Bodyweight, with participants wearing standard 
scrubs, was measured at pre-intervention, weekly during inter-
vention, and post-intervention using an electronic scale that 
was calibrated annually (CC Vaughan & Sons, Incorporated, 
Columbia, SC).
Previous evidence suggests that both hypocaloric diet and 
sleep restriction could affect physical activity [40, 41], which 
may subsequently affect glucose control and lipoprotein profile. 
Thus, physical activity at pre- and post-intervention were quan-
tified by the actigraphy monitor (ActiGraph GT3X+, ActiGraph, 
Pensacola, FL) using manufactured provided software (Actilife 
version 6.11). This monitor quantifies accelerations resulting 
from physical activity-associated bodily motion at a fixed point 
of the body to determine physical activity intensities. Physical 
activity counts per minute per day were determined by com-
bining the magnitude of sampled acceleration from all three 
axes measured by the monitor as an integrated measure of 
physical activity. Previously, physical activity counts measured 
by the Actigraph GT3X+ worn on the wrist and on the waist 
were found to be strongly correlated as a non-intensity specific 
measure of physical activity [42] and was therefore included as 
a measure of total physical activity.
Serum sample collection
Venous blood samples were collected in a BD serum Vacutainer 
following a minimum of a 12-hour fast (not including water), 
between 06:00 and 09:00 hours, at pre- and post-intervention. 
Following approximately 30 minutes allowing the blood to clot, 
the whole blood was centrifuged at 3000 rpm at 4°C for 20 min-
utes. Serum separated after centrifugation was aliquoted and 
stored at −80°C until all participant samples were ready for 
analysis.
Lipoprotein subclass particle concentrations and 
sizes, and NMR-calculated values
Serum samples were analyzed by LipoScience, Inc. (Raleigh, NC) 
for determination of lipoprotein subclass particle concentrations 
and sizes by nuclear magnetic resonance (NMR) spectroscopy. 
The LipoProfile-3 algorithm [43] was used to determine concen-
trations of small, medium, and large (including chylomicron) 
very-low-density lipoprotein particle (VLDL-P) and HDL-P, small 
and large LDL-P and intermediate-density lipoprotein particle 
(IDL-P). Weighted-average VLDL-P, LDL-P, and HDL-P diameter 
was calculated as the sum of the lipoprotein subclass diam-
eters multiplied by its relative mass percentage as estimated 
from the amplitude of its methyl NMR signal. Apolipoprotein B 
(ApoB)-containing lipoprotein particles, including VLDL-P, IDL-
P, and LDL-P, possess atherogenic properties [44]; thus, ApoB-
containing lipoprotein concentration was calculated as the sum 
of the three. Total TG and HDL-C concentrations were calculated 
by NMR. In addition, a lipoprotein insulin resistance score (LP-
IR), an index for insulin sensitivity [45], was also calculated.
Glucose, glucose regulatory hormones and indices of 
insulin sensitivity
Serum glucose concentrations were analyzed in duplicate sam-
ples using YSI 2300 STAT Plus (YSI Life Sciences, Yellow Springs, 
OH), which was calibrated according to manufacturer instruc-
tion. A single Bio-Plex Pro Human Diabetes Panel 10-Plex assay 
(BIO-RAD Laboratories, Hercules, CA) was used to analyze serum 
concentrations in duplicate samples of insulin, glucagon, gas-
tric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-
1), visfatin and resistin using a MAGPIX system (Luminex 
Corporation, Austin, TX) following manufacturer instruction. 
Insulin and glucagon are hormones that regulate glucose con-
centrations. GIP and GLP-1 are incretins that stimulate insulin 
secretion [46–48]. Visfatin mimics insulin [49] and resistin pro-
motes insulin resistance [50].
The updated homeostasis model assessment of insulin re-
sistance (HOMA2-IR) was calculated using the HOMA Calculator 
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that influence circulating glucose and insulin levels in order to 
provide model-derived estimates of insulin resistance [51, 52]. 
The quantitative insulin-sensitivity check index (QUICKI) was 
calculated as 1/[log(I)+log(G)], where I  and G were concentra-
tions of fasting insulin and glucose, respectively [53].
Statistical analysis
Statistical analysis was performed using SAS version 9.4 (Cary, 
NC). The Shapiro-Wilk and Kolmogorov-Smirnov tests were per-
formed to test whether the data were normally distributed. Non-
normally distributed data were transformed using log(10) to be 
used in statistical models. Pre-intervention values were com-
pared between CR and CR+SR using independent t-test or Chi-
square test as appropriate. A general linear model with repeated 
measures, including a group×time interaction, was utilized to 
determine if any variables changed differently between the two 
groups following their respective interventions. Pre-intervention 
body weight or change in body weight was adjusted in the gen-
eral linear models to account for potential influences of these 
variables. Paired sample t-tests were performed within each 
group to compare pre- and post-intervention values and effect 
sizes (Cohen’s d and partial Eta Squared) were also calculated. 
Change values were calculated by subtracting pre-intervention 




Participant characteristics prior to the intervention are shown 
in Table 1. No differences between the CR and CR+SR groups for 
age, sex or race composition, height, blood pressure, proportion 
of participants having signs of mild or moderate sleep apnea, 
calorie intake, or total physical activity were found. However, 
body weight and BMI were significantly greater in the CR+SR 
group compared to the CR group. This sub-sample was compar-
able in these characteristics to the full sample.
The CR and CR+SR groups had similar degree of calorie re-
striction compared to pre-intervention throughout the 8 weeks 
(14.0 ± 9.2% and 17.8 ± 7.9%, p = 0.264). After the intervention, 
body weight significantly decreased in both groups with no sig-
nificant difference found in the amount of absolute or percent 
weight loss between groups (p = 0.974 and 0.818, respectively). 
The amount of weight loss in this sub-sample was also compar-
able to the full sample.
Total physical activity did not change differently between the 
two groups from pre- to post-intervention (p = 0.454 for group 
× time interaction). There was no significant change found in 
physical activity within either the CR or CR+SR group (p = 0.132 
and 0.500, respectively) or in the overall sample (p = 0.119).
Sleep duration, midpoint sleep time, and self-
reported questionnaires and assessment
No differences in TIB, TST, or midpoint sleep time between CR 
and CR+SR groups prior to intervention were found (Table 2). 
For the CR+SR group, TIB and TST were shorter on the 5 days 
when sleep was restricted, by 49 and 66 minutes on average, 
respectively, and longer on the 2 ad libitum days, by 75 and 57 
minutes on average, respectively, during the 8-week interven-
tion compared to pre-intervention values. For the CR group, both 
TIB and TST remained stable throughout the intervention. The 
difference between midpoint sleep time on sleep-restricted days 
and ad libitum sleep days for the CR+SR group was not different 
from the difference in midpoint sleep on workdays and free 
days for the CR group (p = 0.412).
Presented in Supplementary Table 1 are the scores of 
self-administered questionnaires and assessments at pre-
intervention and every 2 weeks throughout intervention. No par-
ticipant in either the CR or CR+SR group had changes that met 
the pre-determined criteria for exclusion during the intervention.
Lipoprotein subclass particle concentrations 
and sizes
Fasting serum lipoprotein subclass particle concentrations and 
sizes are found in Table 3. Prior to intervention, no significant 
differences in any of the lipoprotein subclass particle concentra-
tions or sizes were found between the CR and CR+SR groups (p ≥ 
0.187 for all), which persisted after adjusting for pre-intervention 
body weight (p ≥ 0.141 for all).
Although the differences between the CR and CR+SR groups 
in the changes in mean HDL-P size and TG concentration (NMR-
calculated) were not statistically significant (p for group × time 
interaction  =  0.066 and 0.077, respectively), we further exam-
ined the changes within each group given the small sample 
size and exploratory nature of the study. Mean HDL-P size de-
creased in the CR+SR group with medium effect size (Cohen’s 
d = 0.50, p = 0.022), but did not change in the CR group (Cohen’s 
d = 0.00, p = 0.790) (Figure 2). TG concentration did not change 
significantly in either group and the effect sizes were small (CR: 
Cohen’s d = 0.16, p = 0.078; CR+SR: Cohen’s d = 0.47, p = 0.269; 
using transformed data).
All other NMR-determined concentrations and sizes did not 
change differently from pre- to post-intervention between the 
CR and CR+SR groups. After adjustment for pre-intervention 
weight or weight change from pre- to post-intervention, the 
changes in CR and CR+SR groups were not different for all lipo-
protein subclass particle concentrations and sizes, and NMR-
calculated variables (all p values for group × time interaction ≥ 
0.109).
Glucose, glucose regulatory hormones, and insulin 
sensitivity indices
Fasting serum concentrations of glucose, insulin, glucagon, GLP-
1, GIP, visfatin, and resistin, and indices of insulin sensitivity 
are presented in Table 4. Prior to the intervention, CR+SR had 
a significantly higher insulin concentration and lower QUICKI 
compared to the CR group (p  =  0.029, and 0.027, respectively). 
Glucose and the other glucose regulatory hormone concentra-
tions, as well as HOMA2-IR index were not different (p > 0.059 
for all). After adjustment for pre-intervention body weight, there 
were no differences at pre-intervention between CR and CR+SR 
groups for any of these concentrations or indices of insulin sen-
sitivity (p ≥ 0.051 for all).
Differential changes from pre- to post-intervention in glu-
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groups. It significantly decreased in the CR group with a large 
effect size of change (Cohen’s d = 0.93, p = 0.016), but did not 
change in the CR+SR group with a small effect size of change 
(Cohen’s d = 0.21, p = 0.701) (Figure 3). Glucagon concentration 
changes were still different following adjustment for body 
weight change from pre- to post-intervention (p for group × 
time interaction  =  0.035). In each group, glucagon changes 
were similar to without adjustment (CR: a large effect size 
reflected by partial Eta Squared  =  0.324, p  =  0.054; CR+SR: a 
small effect size reflected by partial Eta Squared  =  0.010, 
p  =  0.765). Glucagon concentration changes were no longer 
different between the CR and CR+SR groups after adjust-
ment for pre-intervention body weight (p for group × time 
interaction = 0.262).
We also examined changes in visfatin concentration within 
each group, considering the small sample size and a near sig-
nificant group × time interaction (p  =  0.066). Visfatin concen-
tration did not change significantly in either group (p  =  0.170 
and 0.225, for CR and CR+SR, respectively, using transformed 
data). However, it decreased with a medium effect size in the 
CR group (Cohen’s d  =  0.67) but increased with a small effect 
size in the CR+SR group (Cohen’s d = 0.43) (Figure 4). After ad-
justment for pre-intervention body weight or weight change 
from pre- to post-intervention, visfatin concentrations were still 
near statistically different between the CR and CR+SR groups in 
the changes after interventions (p for group × time interaction 
=0.063 and 0.069, respectively).
The CR and CR+SR groups did not change differently from 
pre- to post-intervention in concentrations of glucose, insulin, 
GLP-1, GIP, or resistin, or any index of insulin sensitivity (all p 
values for group × time interaction >0.123). Adjustment for pre-
intervention body weight or weight change from pre- to post-
intervention did not influence these findings (all p values for 
group×time interaction ≥0.140).
Discussion
To our knowledge, this study is the first to examine the effects 
of chronic moderate sleep restriction of ≤90 minutes TIB with 
periodic ad libitum sleep during a calorie restriction weight loss 
intervention in overweight or obese adults. The primary findings 
are that there were differential changes in serum glucagon con-
centration between the CR and CR+SR groups, which decreased in 
the CR group only. Additionally, mean HDL-P size decreased only 
in the CR+SR group, and visfatin concentrations had a medium 
effect size of reduction in the CR group but only a small effect 
size of change in the CR+SR group. The changes in mean HDL-P 
size and visfatin were not statistically different between the CR 
and CR+SR groups, likely due to the small sample size. These data 
suggest that allowing ad libitum sleep on 2 nights per week did 
not prevent the differential changes in mean HDL-P size, and glu-
cagon and visfatin concentrations between the CR and CR+SR 
groups. These findings are in line with recent literature suggesting 
that ad libitum sleep on the weekend did not prevent decreases in 
insulin sensitivity induced by sleep restriction [22].




Age (years) 44.8 ± 6.4 44.2 ± 5.5 0.789
Sex (M/F) 3/9 4/12 1.000
Race (C/AA/H) 5/7 7/8/1 0.655
Height (m) 1.69 ± 0.05 1.71 ± 0.07 0.349
Body mass index (kg/m2) 31.4 ± 2.9 34.5 ± 3.1 0.010
Blood pressure, systolic  
(mmHg)
122.6 ± 8.5 125.3 ± 6.3 0.335
Blood pressure, diastolic  
(mmHg)
79.5 ± 4.1 80.3 ± 5.6 0.699
Apnea-Hypopnea Index†  
 <5 / ≥5 and <15 / ≥15  
and <30 events per hour (n)
6/3/3 8/5/3 0.840
Calorie Intake (kcal/day)
 Pre-Intervention 1642 ± 361 1926 ± 545 0.144
 During intervention 1395 ± 257 1562 ± 379 0.216
Bodyweight (kg)
 Pre-Intervention 89.2 ± 9.2 100.8 ± 9.3 0.003
 Post-Intervention 86.4 ± 8.8‡ 98.0 ± 9.9‡  
Physical activity (counts/minute/day)
 Pre-Intervention 1633 ± 371 1558 ± 301 0.556
 Post-Intervention 1761 ± 414 1582 ± 413  
Data presented as Mean ± SD. CR: calorie restriction; CR+SR: calorie restriction 
and sleep restriction. C: Caucasian; AA: African American; H: Hispanic. Listed p 
values are for comparisons between CR and CR+SR at pre-intervention. The p 
values in bold are < 0.05. 
*The subset of participants who also had glucose regulatory hormones data 
(n = 11) had similar values to these reported here.
†Assessed by WatchPat (Itamar Medical, Israel) home testing.
‡p < 0.05 significant difference from pre- to post-intervention within the spe-
cific group.
Table 2. Time in bed (TIB) and total sleep time (TST) at pre-intervention and during intervention, and midpoint sleep time by intervention 
group
CR (n = 12) CR+SR (n = 16)
Pre-intervention During intervention Pre-intervention During intervention
Average TIB (min/day) 421.6 ± 67.2 422.3 ± 26.4 423.6 ± 75.0 408.9 ± 52.7
 Sleep restricted days    379.9 ± 7.0§
 Ad libitum sleep days    504.0 ± 18.0§
Average TST (min/day) 372.9 ± 69.6 374.0 ± 49.3 367.9 ± 68.4 353.8 ± 47.4
 Sleep restricted days    314.1 ± 16.7*
 Ad libitum days    437.2 ± 18.6*
Midpoint sleep time (HH:MM) 03:07 ± 00:51 03:13 ± 00:30 02:48 ± 01:23 03:16 ± 01:24
 Sleep restricted or workdays  03:01 ± 00:35  03:05 ± 01:29
 Ad libitum or free days  03:24 ± 00:32  03:27 ± 01:25
Data presented as Mean ± SD. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction.
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Lipoprotein subclass particle concentrations 
and sizes
Due to the small number of studies completed, how sleep re-
striction may affect the lipoprotein profile remain inconclusive. 
Reynolds et al. found that TG concentration was lower following 
five nights of 4-hour TIB compared to two nights of 10-hour TIB 
in healthy weight adults [54]. However, O’Keeffe et al. found no 
changes in total cholesterol, HDL-C, or TG concentrations fol-
lowing five nights of 4-hour TIB compared to 9-hour TIB in a ran-
domized cross-over trial of young normal weight adults [55]. In 
healthy adults undergoing five nights of 4-hour TIB compared 
to controls achieving five nights of >7-hour TIB, small, medium, 
and large LDL-P, small VLDL-P, and ApoB concentrations de-
creased with no changes in small, medium, or large HDL-P con-
centrations [26].
To date, we are not aware of any study that has examined 
the influence of prolonged period of sleep restriction on lipo-
protein profile. Aho at el. examined the putative effects of 
prolonged insufficient sleep, assessed by self-report, using two 
independent large sample epidemiologic cohorts [26]. They 
found that large and extra-large HDL-P concentrations were 
lower among individuals who reported subjective sleep in-
sufficiency compared to individuals without subjective sleep 
insufficiency. Our study found mean HDL-P size decreased in 
the CR+SR group but not the CR group. Given that larger HDL-P 
size is associated with lower cardiovascular disease risk [12], 
these results suggest that lipoprotein profile was negatively 
influenced by the addition of sleep restriction to calorie re-
striction in the CR+SR group when compared to CR weight loss 
alone in overweight or obese adults.
Glucose, glucose regulatory hormones, and insulin 
sensitivity indices
In our study, glucose and insulin concentrations did not have dif-
ferential changes between the CR and CR+SR groups; however, 
Table 3. Lipoprotein subclass particle concentrations and sizes, and NMR-calculated values at pre- and post-intervention by intervention group









CHY-P and VLDL-P Concentration (nmol/L)  
 Total CHY-P and VLDL-P 47.2 ± 19.1 43.2 ± 22.6 41.8 ± 16.7 48.8 ± 20.8 0.104
 Large CHY-P and VLDL-P 2.6 (0.5–11.2) 4.3 ± 3.5 3.6 ± 2.4 3.8 ± 1.7  
 0.45 ± 0.45 0.47 ± 0.42 0.44 ± 0.37 0.53 ± 0.23 0.507†
 Medium VLDL-P 10.6 ± 7.5 6.9 (0.6–26.9) 7.6 (1.6–21.9) 6.5 (0.2–29.8)  
 0.92 ± 0.33 0.75 ± 0.44 0.76 ± 0.33 0.72 ± 0.51 0.450†
 Small VLDL-P 32.3 ± 18.9 30.8 ± 18.9 30.8 ± 13.2 36.8 ± 17.8 0.224
LDL-P and IDL-P Concentration (nmol/L)
 Total LDL-P 1008 ± 249 861 (685–1389) 882 ± 240 925 ± 261  
 2.99 ± 0.11 2.97 ± 0.12 2.93 ± 0.12 2.95 ± 0.14 0.301†
 IDL-P 217 ± 114 184 ± 130 202 ± 85 184 ± 103 0.662
 Large LDL-P 324 ± 241 361 ± 257 184 (0.0–770) 253 (0.0–758)  
 2.36 ± 0.54 2.54 ± 0.36 2.39 ± 0.51 2.52 ± 0.38 0.289†
 Small LDL-P 467 ± 276 431 ± 280 399 ± 165 453 ± 217 0.229
Apo-B Containing Lipoprotein-P  
Concentration (nmol/L)
1055 ± 255 928 (730–1425) 923 ± 238 974 ± 272  
3.01 ± 0.11 2.99 ± 0.12 2.95 ± 0.11 2.97 ± 0.13 0.251†
HDL-P Concentration (µmol/L)
 Total HDL-P 28.5 ± 7.5 27.1 ± 8.1 27.4 ± 11.5 26.5 ± 10.9 0.883
 Large HDL-P 6.7 (3.3–13.6) 6.8 ± 3.9 7.4 ± 3.2 6.4 ± 3.0  
 0.83 ± 0.22 0.76 ± 0.28 0.82 ± 0.22 0.76 ± 0.21 0.927†
 Medium HDL-P 7.1 ± 4.6 8.1 ± 5.3 7.3 (3.8–19.0) 9.1 ± 4.4  
 0.84 ± 0.23 0.87 ± 0.31 0.91 ± 0.21 0.91 ± 0.22 0.917†
 Small HDL-P 13.8 ± 8.6 12.2 ± 8.5 10.8 ± 7.9 11.0 ± 9.0 0.552
Mean Particle Size (nm)
 VLDL-P 50.7 ± 7.0 49.5 ± 6.5 49.8 ± 5.9 50.4 ± 7.2 0.506
 LDL-P 20.8 ± 0.8 20.9 (19.7–21.5)  20.7 ± 0.8 21.0 (19.6–22.1)  
 1.32 ± 0.02 1.31 ± 0.01 1.32 ± 0.02 1.32 ± 0.02 0.491†
 HDL-P 9.7 ± 0.8 9.7 ± 0.7 9.9 ± 0.6 9.6 ± 0.6 0.066
NMR-calculated values (mg/dL)
 TG 104.4 ± 56.0 91.4 ± 55.1 65.0 (24.0– 
158.0)
91.8 ± 40.4  
 1.96 ± 0.24 1.88 ± 0.27 1.85 ± 0.23 1.92 ± 0.20 0.077†
 HDL-C 49.6 ± 18.6 45.9 ± 19.4 46.5 ± 22.3 43.2 ± 21.4 0.941
LP-IR Score 44.8 ± 23.6 43.3 ± 24.1 40.4 ± 15.5 46.1 ± 17.0 0.202
Normally distributed data are presented as Mean ± SD; non-normally distributed data are presented as median (lower quartile-upper quartile) and log(10) trans-
formed (mean ± SD) underneath. NMR: nuclear magnetic resonance; CR: calorie restriction; CR+SR: calorie restriction and sleep restriction; CHY-P/C: chylomicron 
particle/cholesterol; VLDL-P/C: very-low-density lipoprotein particle/cholesterol; LDL-P/C: low-density lipoprotein particle/cholesterol; IDL-P: intermediate-density 
lipoprotein particle; TG: triglyceride; Apo-B: apolipoprotein-B; HDL-P/C: high-density lipoprotein particle/cholesterol; LP-IR: lipoprotein insulin resistance
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glucagon concentration decreased in the CR group but did not 
change in CR+SR group. The two previous studies involving 
sleep restriction during calorie restriction did not measure glu-
cagon [29, 30]. St-Onge et al. did not find differences in fasting 
or average glucose and insulin concentrations in the morning, 
afternoon, or at night between two different sleep opportun-
ities, 4-hour and 9-hour TIB, in normal weight men and women 
[30]. Nedeltcheva et al. noted that during a 14-day combined ex-
posure to hypocaloric diet and short sleep periods, lower levels 
of fasting and 24-hour insulin concentrations following 5.5-
hours of sleep opportunity versus 8.5-hours were found in over-
weight individuals (BMI=27.4±2.0 kg/m2) [29]. These changes are 
consistent with a state of reduced carbohydrate availability po-
tentially induced by calorie restriction. The weight loss in their 
study was similar with our study, ~3–4% weight loss. These two 
studies did not suggest sleep restriction during a short period 
of calorie deficit had adverse effects on glucose metabolism. In 
contrast, our results suggest adverse effects of sleep restriction 
during a longer calorie restriction intervention period in parti-
cipants who had a higher BMI than participants in the two pre-
vious studies. These results are important given that calorie 
restriction for a few weeks may be used more by obese individ-
uals than overweight and normal weight individuals in order to 
obtain health benefits.
Visfatin is an adipocytokine known to possess insulin-
mimetic properties, functions to activate insulin receptors, and 
acts as a determinant of insulin resistance in obesity [49]. A pre-
vious study in middle-aged, obese females who slept less than 6 
hours found higher circulating visfatin concentration and lower 
insulin sensitivity compared to women who achieved adequate 
sleep [56]. A two-month intervention was implemented in these 
women to increase the amount of sleep achieved each night and 
found that visfatin concentration decreased and insulin sensi-
tivity increased. In our study, visfatin concentration decreased 
in the CR group with medium effect size, suggesting the non-
significant finding in this group was likely due to the small 
sample size. These results are in line with previous study find-
ings that sleep restriction potentially increases visfatin concen-
trations. However, no differential changes were found between 
CR and CR+SR groups in insulin sensitivity from pre- to post-
intervention, as indicated by their similar changes in HOMA2-IR, 
QUICKI, and LP-IR.
A few explanations exist for the lack of differential changes 
in insulin sensitivity from pre- to post-intervention between 
the CR and CR+SR groups. One reason is the influence of recent 
nights’ sleep. Previously, insulin sensitivity is influenced by only 
2–3 nights of restricted or extended sleep [21, 57]. We did not 
control the last 2–3 nights’ sleep duration before blood sampling 
in our study, as the CR+SR group chose their restricted and ad 
libitum sleep days. Therefore, we were not able to determine if 
any chronic effect due to the 8-week intervention that occurred 
was influenced by recent nights’ sleep. These data suggest that 
any influence of chronic moderate sleep restriction with peri-
odic ad libitum sleep on insulin sensitivity, compared to the 
effect of weight loss, was not substantial. Second, similar to the 
study performed by Zielinski et al. [23], the possibility remains 
that the duration of the intervention may have allowed for 
chronic adaptations to occur due to sleep restriction. Lastly, the 
degree of sleep restriction in our study may not be large enough 
to influence insulin sensitivity.
The way in which accessory glucose regulatory hormones, 
such as GIP, GLP-1, and resistin, relate to sleep restriction during 
calorie restriction has yet to be elucidated. GIP is an incretin 
which stimulates insulin secretion but does not inhibit glucagon 
secretion and is known to be elevated in individuals with im-
paired glucose metabolism [47]. GLP-1 is another incretin that 
stimulates glucose-dependent insulin secretion when plasma 
glucose concentration is high, but not when plasma glucose 
concentration falls below a normal range [46, 48]. Lastly, resistin, 
an adipocytokine, is altered in obese adults [50]. The study by 
St-Onge et  al. found no differences in fasting GLP-1 following 
4-hour vs. 9-hour TIB with a controlled diet [30]. Thus, our find-
ings are in line with previous results suggesting that fasting 
GLP-1 concentration may not be directly influenced by modest 
weight loss in the presence or absence of moderate sleep 
restriction.
Strengths and limitations
This study adds important information to the literature re-
garding the effects of sleep restriction in the context of cal-
orie restriction on cardiometabolic health outcomes. Very few 
studies have examined outcomes in this nature, and, to our 
knowledge, this study has been the only study completed exam-
ining a sleep restriction intervention lasting several weeks. 
This 8-week study duration is considerably longer than other 
controlled studies examining sleep restriction. Our study was 
unique in that it involves modest sleep restriction, an average of 
less than 90 minutes per day shorter TIB on 5 days a week, and 
ad libitum sleep on the other 2 days of the week. By allowing par-
ticipants to choose restricted sleep days make the results more 
generalizable to the larger populations where catch-up sleep oc-
curs throughout the week. In addition, the average difference in 
midpoint sleep on sleep restricted days and ad libitum days in 
Figure 2. Mean high-density lipoprotein particle (HDL-P) size at pre- and post-
intervention by intervention group. Error bars represent standard error of the 
mean. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction. 
*p  = 0.066 for group×time interaction. **p  = 0.022 for pre- to post-intervention 






/sleepadvances/article/1/1/zpab001/6122555 by guest on 04 M
arch 2021
Sparks et al. | 9
the CR+SR group was less than one hour and not different com-
pared to the workday and free day difference in the CR group. 
Social Jetlag of greater than 1 hour compared to less than 1 hour, 
specifically, the difference in sleep schedule on weekdays and 
weekend days, was previously found to be associated with in-
creased metabolic syndrome risk and diabetes/prediabetes [58]. 
Therefore, the sleep timing differences were unlikely to con-
tribute to our findings regarding group differences.
A few limitations also exist. First, only a single fasting blood 
sample was collected at pre- and post-intervention. Therefore, 
variables of interest, specifically glucose and its regulatory hor-
mones, were not measured after meals or throughout 24-hour 
period. We did not control the previous few nights’ sleep, which 
may influence the results as we discussed above. We did not use 
more advanced techniques, such as the insulin clamp, which is 
more sensitive to changes in glucose metabolism. Second, this 
study is from a clinical trial with different primary outcomes 
where blood samples were only available from a subset of par-
ticipants. As such, statistical power was not determined a priori. 
As a result, some findings were of medium effect sizes for the 
degree of change from pre- to post-intervention, but not statis-
tically significant.
The small sample size also did not allow us to examine 
sex or racial differences within or between groups. In both 
groups, 75% of participants were women; if there were sex 
differences in any outcomes, the results may be more in-
fluenced by women than men participants. We also did not 
Table 4. Glucose, its regulatory hormones, and indices of insulin sensitivity at pre- and post-intervention by intervention group
CR (n = 12) CR+SR (n = 11) Group×time interaction
Pre-intervention Post-intervention Pre-intervention Post-intervention p value
Glucose (mg/dL) 76.3 ± 16.6 74.4 ± 17.1 91.6 ± 20.1 82.5 ± 17.4 0.123
Insulin (uU/mL) 6.6 (0.8–31.7)  
0.77 ± 0.43
5.3 (1.8–24.4)  
0.78 ± 0.32
15.6 ± 8.4ǂ  
1.13 ± 0.26
13.9 (3.3–44.3)  
1.05 ± 0.34 0.491†
Glucagon (ƥg/mL) 1776 (1428–2631)  
3.26 ± 0.07
1823 ± 317  
3.18 ± 0.07
1789 ± 243  
3.25 ± 0.06
1771 ± 278  
3.24 ± 0.07 0.028†
GLP-1 (ƥg/mL) 231 ± 95  
2.34 ± 0.16
185 ± 70  
2.16 ± 0.46
186 ± 41  
2.26 ± 0.11
154 (87–525)  
2.25 ± 0.22 0.166†
GIP (ƥg/mL) 367 (260–819)  
2.61 ± 0.17
322 ± 70  
2.50 ± 0.10
382 ± 135  
2.56 ± 0.15
349 (149–2223)  
2.57 ± 0.31 0.169†
Visfatin (ƥg/mL) 5513 ± 2462  
3.71 ± 0.18
4161 ± 1405  
3.59 ± 0.16
3883 ± 1659  
3.55 ± 0.20
3992 (1377–15772)  
3.66 ± 0.27 0.066†
Resistin (ƥg/mL) 5677 (2845–22092)  
3.82 ± 0.25
5515 (3496–13999)  
3.81 ± 0.21
5802 ± 1478  
3.75 ± 0.12
5718 (3312–23666)  
3.83 ± 0.26 0.240†
HOMA2-IR 1.25 (0.42–4.15)  
0.05 ± 0.32
0.73 (0.52–3.27)  
0.05 ± 0.26
1.89 (0.49–4.17)  
0.23 ± 0.27
1.72 (0.38–5.59)  
0.14 ± 0.34 0.969†
QUICKI 0.39 ± 0.08 0.39 ± 0.05 0.32 ± 0.04ǂ 0.34 ± 0.05 0.316
Normally-distributed data are presented as Mean±SD; non-normally distributed data are presented as median (lower quartile-upper quartile) and log(10) trans-
formed (mean ± SD) underneath. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction; GLP-1: glucagon-like peptide-1; GIP: gastric inhibitory peptide; 
HOMA2-IR: updated homeostasis model assessment of insulin resistance; QUICKI: quantitative insulin-sensitivity check index. The p values in bold are < 0.05.
ǂp < 0.05 significant difference at pre-intervention between groups; †p value for test using transformed data.
Figure 3. Serum glucagon concentration [log(10) transformed] at pre- and post-
intervention by intervention group. Error bars represent standard error of the 
mean. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction. 
*p  = 0.028 for group×time interaction. **p  = 0.016 for pre- to post-intervention 
comparison within CR group.
Figure 4. Serum visfatin concentration [log(10) transformed] at pre- and post-
intervention by intervention group. Error bars represent standard error of the 
mean. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction. 
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control menstrual cycle phase of the blood sample collection 
date. The sample characteristics and small sample size limit 
the generalizability of the results. Although the statistical 
methods of repeated measures analysis accounted for the 
pre-intervention values, differences between CR and CR+SR 
in pre-intervention body weight, insulin and QUICKI, could 
impact the findings that cannot be completely addressed by 
statistical analysis. Specifically, greater body weight, higher 
insulin concentration, and lower QUICKI in the CR+SR group 
suggest this group may be less metabolically healthy than the 
CR group at baseline. This may contribute to different changes 
in response to interventions even though the primary differ-
ences found between the two groups were not these three 
outcomes per se.
Conclusion
In this study, 8 weeks of calorie restriction with and without sleep 
restriction of less than 90 minutes per day on 5 days with 2 days 
of ad libitum sleep per week, resulted in similar degrees of weight 
loss. However, differential changes in serum glucagon concentra-
tion were found between the CR and CR+SR groups. Our findings 
also suggest differential changes in mean HDL-P size and visfatin 
concentrations between the CR and CR+SR groups. These find-
ings suggest this moderate amount of sleep restriction, despite 
periodic catch-up sleep, influenced glucose regulation and lipo-
protein metabolism. Thus, individuals who are pursuing weight 
loss should be encouraged to avoid short sleep on some days to 
prevent potential undesirable influence on glucose and lipopro-
tein metabolism in order to obtain better weight loss outcomes.
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Supplementary material is available at SLEEP Advances online.
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